Annexon, INC Form 4 insider transactions

Muneer A. Satter, a Director and 10% Owner of Annexon, Inc., was granted 55,000 stock options with an exercise price of $2.55, vesting on the first anniversary of the grant date or the next annual meeting.

Annexon, Inc. director William D. Waddill was granted 55,000 stock options with an exercise price of $2.55, vesting over the next year or by the next annual meeting.

Annexon, Inc. Director William H. Carson was granted 55,000 stock options with an exercise price of $2.55, vesting on the earlier of June 5, 2026, or the next Annual Meeting.

Annexon, Inc. Director Jung Choi was granted 55,000 stock options with an exercise price of $2.55, vesting over the next year or by the next annual meeting.

Annexon, Inc. Director William A. Jones Jr. was granted 55,000 stock options with an exercise price of $2.55, aligning his interests with shareholder value.

Annexon, Inc. Director Bettina M. Cockroft has been granted 55,000 stock options with an exercise price of $2.55, vesting over the next year, as reported in a recent SEC Form 4 filing.

Dean Richard Artis, EVP & Chief Scientific Officer of Annexon, Inc., reports acquisition of shares and stock options.

Chief Medical Officer Jamie Dananberg reports acquisition of stock options and restricted stock units in Annexon, Inc.

EVP and CFO of Annexon, Jennifer Lew, reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Annexon's CEO, Douglas Love, reports the acquisition of 1,300,000 stock options with a vesting schedule commencing on February 27, 2025.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., reports the acquisition of stock options and restricted stock units.

Michael Overdorf, EVP & Chief Business Officer of Annexon, Inc., reports the acquisition of stock options and restricted stock units.

Chief Medical Officer Jamie Dananberg reports the sale of 5,521 shares of Annexon, Inc. common stock to cover tax obligations related to vesting restricted stock units.

EVP and Chief Scientific Officer of Annexon, Richard Artis, sold 5,515 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., sold 8,345 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Michael Overdorf, EVP & Chief Business Officer of Annexon, Inc., sold 6,618 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

EVP and CFO of Annexon, Jennifer Lew, sold 6,912 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Annexon's CEO, Douglas Love, sold 5,021 shares of common stock on February 13, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Michael Overdorf, EVP & Chief Business Officer of Annexon, Inc., sold 1,425 shares of common stock on February 13, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Jennifer Lew, EVP & CFO of Annexon, Inc., reported selling 1,786 shares of common stock on February 13, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., sold 1,783 shares of common stock on February 13, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Director William A. Jones Jr. of Annexon, Inc. acquired 88,000 stock options on January 9, 2025, which vest monthly over three years.

Annexon's CEO, Douglas Love, exercised stock options and acquired 37,994 shares of common stock on January 6, 2025.

Director William H. Carson of Annexon, Inc. engaged in stock transactions, including the purchase of 3,200 shares and the disposal of 25,600 shares, under a pre-arranged 10b5-1 trading plan.

Annexon's CEO, Douglas Love, executed stock options at a price of $1.8501, resulting in adjustments to his holdings of common stock.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director William H. Carson of Annexon, Inc. reports a transaction involving the purchase and sale of company stock under a pre-arranged 10b5-1 trading plan.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., sold 4,500 shares of common stock at $7.10 per share on September 19, 2024, under a pre-arranged 10b5-1 trading plan.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., sold 5,500 shares of common stock at a price of $6.16 per share on September 12, 2024, according to a Form 4 filing.

Ted Yednock, EVP & Chief Innovation Officer of Annexon, Inc., sold 5,500 shares of common stock on September 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.